35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer Article Swipe

PDF

Oliver Gautschi , Alexander Drilon , Benjamin Solomon , Pascale Tomasini , Herbert H. Loong , Filippo de Braud , Kōichi Goto , Patrick Peterson , Scott Barker , Katherine Liming , Bente Frimodt‐Moller , K. Park ·

YOU? · · 2024 · Open Access · · DOI: https://doi.org/10.1016/j.esmoop.2024.102614

Selpercatinib is a highly selective and potent CNS-active RET kinase inhibitor approved for the treatment of RET fusion-positive NSCLC based on the results of the phase I/II trial LIBRETTO-001 (NCT03157128). The final LIBRETTO-001 data for NSCLC is reported. Patients with advanced, RET fusion-positive (identified by NGS, PCR or FISH) NSCLC who were treatment naïve or who had previously received platinum-based chemotherapy were enrolled at a selpercatinib dose of 160 mg BID. The primary end point was objective response rate (ORR) by RECIST 1.1 assessed by an independent review committee. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. In 69 treatment naïve patients, the ORR was 83% with a mDoR of 20.3 mo (median follow-up 37.1 mo) and mPFS of 22.0 mo (Table). In 247 patients who had previously received platinum-based chemotherapy, the ORR was 62% with a mDoR of 31.6 mo (median follow-up 39.5 mo) and mPFS of 26.2 mo. Across both groups, 26 patients had measurable CNS metastases at baseline, the CNS-ORR was 85% with a CNS-mDoR of 9.4 mo (median follow up 25.8 mo) and CNS-mPFS of 11.0 mo. At the 36 mo landmark estimate, 57% of previously treated patients and 66% of treatment naïve patients were alive. The overall safety profile was consistent with previous reports. The most common adverse events (AEs) ≥G3 in ≥10% patients were hypertension and increased AST/ALT. Dose reduction from any cause occurred in 53% of patients. In total 11% discontinued treatment due to AEs, including 4% due to AEs related to selpercatinib as assessed by the investigator.Table: 35PPreviously treated with platinum-based chemotherapy N=247Treatment naïve N=69ORR, % (95% CI)62 (55, 68)83 (72, 91)mTime to Response, mo1.91.8mDoR, mo (95% CI)31.6 (20.4, 42.3)20.3 (15.4, 29.5)Censoring, %49.343.9Median follow-up, mo39.537.136 mo DoR, %44.7 (35.7, 53.4)35.4 (22.0, 49.0)mPFS, mo (95% CI)26.2 (19.3, 35.7)22.0 (16.5, 24.9)Censoring, %46.244.9Median follow-up, mo41.238.936 mo PFS, %41.1 (34.2, 47.9)34.6 (22.3, 47.3)mOS, mo (95% CI)47.6 (35.9, NE)NE (37.8, NE)Censoring, %55.562.3Median follow-up, mo44.641.936 mo OS, %56.6 (49.8, 62.8)65.6 (52.4, 75.9) Open table in a new tab In the final analysis, selpercatinib continued to show durable responses and intracranial activity with a manageable safety profile in patients with RET fusion-positive NSCLC. These data and the recent positive results from the phase III trial LIBRETTO-431, reinforce the importance of genomic testing to identify RET fusions at initial diagnosis.

Related Topics

Concepts

Fusion Lung cancer Cell Medicine Internal medicine Oncology Cancer research Biology Philosophy Linguistics Genetics

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1016/j.esmoop.2024.102614
PDF: http://www.esmoopen.com/article/S205970292400382X/pdf
OA Status: gold
Cited By: 8
Related Works: 10
OpenAlex ID: https://openalex.org/W4393165832

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4393165832

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1016/j.esmoop.2024.102614

Digital Object Identifier
Title: 35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2024

Year of publication
Publication date: 2024-03-01

Full publication date if available
Authors: Oliver Gautschi, Alexander Drilon, Benjamin Solomon, Pascale Tomasini, Herbert H. Loong, Filippo de Braud, Kōichi Goto, Patrick Peterson, Scott Barker, Katherine Liming, Bente Frimodt‐Moller, K. Park

List of authors in order
Landing page: https://doi.org/10.1016/j.esmoop.2024.102614

Publisher landing page
PDF URL: https://www.esmoopen.com/article/S205970292400382X/pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://www.esmoopen.com/article/S205970292400382X/pdf

Direct OA link when available
Concepts: Fusion, Lung cancer, Cell, Medicine, Internal medicine, Oncology, Cancer research, Biology, Philosophy, Linguistics, Genetics

Top concepts (fields/topics) attached by OpenAlex
Cited by: 8

Total citation count in OpenAlex
Citations by year (recent): 2025: 5, 2024: 3

Per-year citation counts (last 5 years)
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4393165832
doi	https://doi.org/10.1016/j.esmoop.2024.102614
ids.doi	https://doi.org/10.1016/j.esmoop.2024.102614
ids.openalex	https://openalex.org/W4393165832
fwci	6.90098513
type	article
title	35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
biblio.issue
biblio.volume	9
biblio.last_page	102614
biblio.first_page	102614
grants[0].funder	https://openalex.org/F4320332161
grants[0].award_id	1R01CA251591001A1
grants[0].funder_display_name	National Institutes of Health
grants[1].funder	https://openalex.org/F4320332161
grants[1].award_id	1R01CA273224-01
grants[1].funder_display_name	National Institutes of Health
grants[2].funder	https://openalex.org/F4320332161
grants[2].award_id	P30CA008748
grants[2].funder_display_name	National Institutes of Health
grants[3].funder	https://openalex.org/F4320337351
grants[3].award_id
grants[3].funder_display_name	National Cancer Institute
topics[0].id	https://openalex.org/T10417
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9987000226974487
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2740
topics[0].subfield.display_name	Pulmonary and Respiratory Medicine
topics[0].display_name	Lung Cancer Treatments and Mutations
topics[1].id	https://openalex.org/T10073
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9803000092506409
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2721
topics[1].subfield.display_name	Hepatology
topics[1].display_name	Hepatocellular Carcinoma Treatment and Prognosis
topics[2].id	https://openalex.org/T11067
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9731000065803528
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2730
topics[2].subfield.display_name	Oncology
topics[2].display_name	Colorectal Cancer Treatments and Studies
funders[0].id	https://openalex.org/F4320332161
funders[0].ror	https://ror.org/01cwqze88
funders[0].display_name	National Institutes of Health
funders[1].id	https://openalex.org/F4320337351
funders[1].ror	https://ror.org/040gcmg81
funders[1].display_name	National Cancer Institute
is_xpac	False
apc_list.value	2750
apc_list.currency	EUR
apc_list.value_usd	2965
apc_paid.value	2750
apc_paid.currency	EUR
apc_paid.value_usd	2965
concepts[0].id	https://openalex.org/C158525013
concepts[0].level	2
concepts[0].score	0.4775848388671875
concepts[0].wikidata	https://www.wikidata.org/wiki/Q2593739
concepts[0].display_name	Fusion
concepts[1].id	https://openalex.org/C2776256026
concepts[1].level	2
concepts[1].score	0.4732782542705536
concepts[1].wikidata	https://www.wikidata.org/wiki/Q47912
concepts[1].display_name	Lung cancer
concepts[2].id	https://openalex.org/C1491633281
concepts[2].level	2
concepts[2].score	0.4203704595565796
concepts[2].wikidata	https://www.wikidata.org/wiki/Q7868
concepts[2].display_name	Cell
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.4079045057296753
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C126322002
concepts[4].level	1
concepts[4].score	0.37880080938339233
concepts[4].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[4].display_name	Internal medicine
concepts[5].id	https://openalex.org/C143998085
concepts[5].level	1
concepts[5].score	0.3627820312976837
concepts[5].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[5].display_name	Oncology
concepts[6].id	https://openalex.org/C502942594
concepts[6].level	1
concepts[6].score	0.32099923491477966
concepts[6].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[6].display_name	Cancer research
concepts[7].id	https://openalex.org/C86803240
concepts[7].level	0
concepts[7].score	0.27191030979156494
concepts[7].wikidata	https://www.wikidata.org/wiki/Q420
concepts[7].display_name	Biology
concepts[8].id	https://openalex.org/C138885662
concepts[8].level	0
concepts[8].score	0.14576488733291626
concepts[8].wikidata	https://www.wikidata.org/wiki/Q5891
concepts[8].display_name	Philosophy
concepts[9].id	https://openalex.org/C41895202
concepts[9].level	1
concepts[9].score	0.0
concepts[9].wikidata	https://www.wikidata.org/wiki/Q8162
concepts[9].display_name	Linguistics
concepts[10].id	https://openalex.org/C54355233
concepts[10].level	1
concepts[10].score	0.0
concepts[10].wikidata	https://www.wikidata.org/wiki/Q7162
concepts[10].display_name	Genetics
keywords[0].id	https://openalex.org/keywords/fusion
keywords[0].score	0.4775848388671875
keywords[0].display_name	Fusion
keywords[1].id	https://openalex.org/keywords/lung-cancer
keywords[1].score	0.4732782542705536
keywords[1].display_name	Lung cancer
keywords[2].id	https://openalex.org/keywords/cell
keywords[2].score	0.4203704595565796
keywords[2].display_name	Cell
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.4079045057296753
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/internal-medicine
keywords[4].score	0.37880080938339233
keywords[4].display_name	Internal medicine
keywords[5].id	https://openalex.org/keywords/oncology
keywords[5].score	0.3627820312976837
keywords[5].display_name	Oncology
keywords[6].id	https://openalex.org/keywords/cancer-research
keywords[6].score	0.32099923491477966
keywords[6].display_name	Cancer research
keywords[7].id	https://openalex.org/keywords/biology
keywords[7].score	0.27191030979156494
keywords[7].display_name	Biology
keywords[8].id	https://openalex.org/keywords/philosophy
keywords[8].score	0.14576488733291626
keywords[8].display_name	Philosophy
language	en
locations[0].id	doi:10.1016/j.esmoop.2024.102614
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4210217024
locations[0].source.issn	2059-7029
locations[0].source.type	journal
locations[0].source.is_oa	True
locations[0].source.issn_l	2059-7029
locations[0].source.is_core	True
locations[0].source.is_in_doaj	True
locations[0].source.display_name	ESMO Open
locations[0].source.host_organization	https://openalex.org/P4310320990
locations[0].source.host_organization_name	Elsevier BV
locations[0].source.host_organization_lineage	https://openalex.org/P4310320990
locations[0].license	cc-by-nc-nd
locations[0].pdf_url	http://www.esmoopen.com/article/S205970292400382X/pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc-nd
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	ESMO Open
locations[0].landing_page_url	https://doi.org/10.1016/j.esmoop.2024.102614
indexed_in	crossref, doaj
authorships[0].author.id	https://openalex.org/A5070375776
authorships[0].author.orcid	https://orcid.org/0009-0000-3137-3254
authorships[0].author.display_name	Oliver Gautschi
authorships[0].countries	CH
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210119500
authorships[0].affiliations[0].raw_affiliation_string	Medical Oncology Department, Luzerner Kantonsspital, Luzern, Switzerland
authorships[0].institutions[0].id	https://openalex.org/I4210119500
authorships[0].institutions[0].ror	https://ror.org/02zk3am42
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I4210119500
authorships[0].institutions[0].country_code	CH
authorships[0].institutions[0].display_name	Luzerner Kantonsspital
authorships[0].author_position	first
authorships[0].raw_author_name	O. Gautschi
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Medical Oncology Department, Luzerner Kantonsspital, Luzern, Switzerland
authorships[1].author.id	https://openalex.org/A5063199354
authorships[1].author.orcid	https://orcid.org/0000-0001-6806-9061
authorships[1].author.display_name	Alexander Drilon
authorships[1].countries	US
authorships[1].affiliations[0].institution_ids	https://openalex.org/I1334819555, https://openalex.org/I205783295
authorships[1].affiliations[0].raw_affiliation_string	Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
authorships[1].institutions[0].id	https://openalex.org/I205783295
authorships[1].institutions[0].ror	https://ror.org/05bnh6r87
authorships[1].institutions[0].type	education
authorships[1].institutions[0].lineage	https://openalex.org/I205783295
authorships[1].institutions[0].country_code	US
authorships[1].institutions[0].display_name	Cornell University
authorships[1].institutions[1].id	https://openalex.org/I1334819555
authorships[1].institutions[1].ror	https://ror.org/02yrq0923
authorships[1].institutions[1].type	healthcare
authorships[1].institutions[1].lineage	https://openalex.org/I1334819555
authorships[1].institutions[1].country_code	US
authorships[1].institutions[1].display_name	Memorial Sloan Kettering Cancer Center
authorships[1].author_position	middle
authorships[1].raw_author_name	A. Drilon
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
authorships[2].author.id	https://openalex.org/A5045959942
authorships[2].author.orcid	https://orcid.org/0000-0003-3059-5730
authorships[2].author.display_name	Benjamin Solomon
authorships[2].countries	AU
authorships[2].affiliations[0].institution_ids	https://openalex.org/I2800555584
authorships[2].affiliations[0].raw_affiliation_string	Medical Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
authorships[2].institutions[0].id	https://openalex.org/I2800555584
authorships[2].institutions[0].ror	https://ror.org/02a8bt934
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I2800555584
authorships[2].institutions[0].country_code	AU
authorships[2].institutions[0].display_name	Peter MacCallum Cancer Centre
authorships[2].author_position	middle
authorships[2].raw_author_name	B. Solomon
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Medical Oncology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
authorships[3].author.id	https://openalex.org/A5058623156
authorships[3].author.orcid	https://orcid.org/0000-0002-6474-5912
authorships[3].author.display_name	Pascale Tomasini
authorships[3].countries	FR
authorships[3].affiliations[0].institution_ids	https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I21491767
authorships[3].affiliations[0].raw_affiliation_string	Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital La Timone, CEPCM, Marseille, France
authorships[3].institutions[0].id	https://openalex.org/I21491767
authorships[3].institutions[0].ror	https://ror.org/035xkbk20
authorships[3].institutions[0].type	education
authorships[3].institutions[0].lineage	https://openalex.org/I21491767
authorships[3].institutions[0].country_code	FR
authorships[3].institutions[0].display_name	Aix-Marseille Université
authorships[3].institutions[1].id	https://openalex.org/I1294671590
authorships[3].institutions[1].ror	https://ror.org/02feahw73
authorships[3].institutions[1].type	government
authorships[3].institutions[1].lineage	https://openalex.org/I1294671590
authorships[3].institutions[1].country_code	FR
authorships[3].institutions[1].display_name	Centre National de la Recherche Scientifique
authorships[3].institutions[2].id	https://openalex.org/I154526488
authorships[3].institutions[2].ror	https://ror.org/02vjkv261
authorships[3].institutions[2].type	government
authorships[3].institutions[2].lineage	https://openalex.org/I154526488
authorships[3].institutions[2].country_code	FR
authorships[3].institutions[2].display_name	Inserm
authorships[3].author_position	middle
authorships[3].raw_author_name	P. Tomasini
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital La Timone, CEPCM, Marseille, France
authorships[4].author.id	https://openalex.org/A5032600366
authorships[4].author.orcid	https://orcid.org/0000-0002-6607-1106
authorships[4].author.display_name	Herbert H. Loong
authorships[4].countries	HK
authorships[4].affiliations[0].institution_ids	https://openalex.org/I177725633, https://openalex.org/I4210114914
authorships[4].affiliations[0].raw_affiliation_string	Department of Clinical Oncology, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong SAR, China
authorships[4].institutions[0].id	https://openalex.org/I177725633
authorships[4].institutions[0].ror	https://ror.org/00t33hh48
authorships[4].institutions[0].type	education
authorships[4].institutions[0].lineage	https://openalex.org/I177725633
authorships[4].institutions[0].country_code	HK
authorships[4].institutions[0].display_name	Chinese University of Hong Kong
authorships[4].institutions[1].id	https://openalex.org/I4210114914
authorships[4].institutions[1].ror	https://ror.org/02827ca86
authorships[4].institutions[1].type	healthcare
authorships[4].institutions[1].lineage	https://openalex.org/I1294586568, https://openalex.org/I4210114914
authorships[4].institutions[1].country_code	HK
authorships[4].institutions[1].display_name	Prince of Wales Hospital
authorships[4].author_position	middle
authorships[4].raw_author_name	H.H.F. Loong
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Department of Clinical Oncology, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong SAR, China
authorships[5].author.id	https://openalex.org/A5009935310
authorships[5].author.orcid	https://orcid.org/0000-0003-0103-730X
authorships[5].author.display_name	Filippo de Braud
authorships[5].countries	IT
authorships[5].affiliations[0].institution_ids	https://openalex.org/I4210156707
authorships[5].affiliations[0].raw_affiliation_string	Medical Oncology & Haematology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
authorships[5].institutions[0].id	https://openalex.org/I4210156707
authorships[5].institutions[0].ror	https://ror.org/05dwj7825
authorships[5].institutions[0].type	healthcare
authorships[5].institutions[0].lineage	https://openalex.org/I4210153126, https://openalex.org/I4210156707
authorships[5].institutions[0].country_code	IT
authorships[5].institutions[0].display_name	Fondazione IRCCS Istituto Nazionale dei Tumori
authorships[5].author_position	middle
authorships[5].raw_author_name	F.G.M. De Braud
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Medical Oncology & Haematology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
authorships[6].author.id	https://openalex.org/A5037461196
authorships[6].author.orcid	https://orcid.org/0000-0002-3023-2510
authorships[6].author.display_name	Kōichi Goto
authorships[6].countries	JP
authorships[6].affiliations[0].institution_ids	https://openalex.org/I4210145079
authorships[6].affiliations[0].raw_affiliation_string	National Cancer Center Hospital East, Kashiwa, Chiba, Japan
authorships[6].institutions[0].id	https://openalex.org/I4210145079
authorships[6].institutions[0].ror	https://ror.org/03rm3gk43
authorships[6].institutions[0].type	healthcare
authorships[6].institutions[0].lineage	https://openalex.org/I4210145079
authorships[6].institutions[0].country_code	JP
authorships[6].institutions[0].display_name	National Cancer Center Hospital East
authorships[6].author_position	middle
authorships[6].raw_author_name	K. Goto
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	National Cancer Center Hospital East, Kashiwa, Chiba, Japan
authorships[7].author.id	https://openalex.org/A5103250763
authorships[7].author.orcid	https://orcid.org/0000-0002-2186-6124
authorships[7].author.display_name	Patrick Peterson
authorships[7].countries	US
authorships[7].affiliations[0].institution_ids	https://openalex.org/I168537998
authorships[7].affiliations[0].raw_affiliation_string	Eli Lilly and Company, Indianapolis, IN, USA
authorships[7].institutions[0].id	https://openalex.org/I168537998
authorships[7].institutions[0].ror	https://ror.org/01qat3289
authorships[7].institutions[0].type	company
authorships[7].institutions[0].lineage	https://openalex.org/I168537998
authorships[7].institutions[0].country_code	US
authorships[7].institutions[0].display_name	Eli Lilly (United States)
authorships[7].author_position	middle
authorships[7].raw_author_name	P. Peterson
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Eli Lilly and Company, Indianapolis, IN, USA
authorships[8].author.id	https://openalex.org/A5042945019
authorships[8].author.orcid	https://orcid.org/0000-0001-9372-6932
authorships[8].author.display_name	Scott Barker
authorships[8].countries	US
authorships[8].affiliations[0].institution_ids	https://openalex.org/I168537998
authorships[8].affiliations[0].raw_affiliation_string	Eli Lilly and Company, Indianapolis, IN, USA
authorships[8].institutions[0].id	https://openalex.org/I168537998
authorships[8].institutions[0].ror	https://ror.org/01qat3289
authorships[8].institutions[0].type	company
authorships[8].institutions[0].lineage	https://openalex.org/I168537998
authorships[8].institutions[0].country_code	US
authorships[8].institutions[0].display_name	Eli Lilly (United States)
authorships[8].author_position	middle
authorships[8].raw_author_name	S. Barker
authorships[8].is_corresponding	False
authorships[8].raw_affiliation_strings	Eli Lilly and Company, Indianapolis, IN, USA
authorships[9].author.id	https://openalex.org/A5091804073
authorships[9].author.orcid
authorships[9].author.display_name	Katherine Liming
authorships[9].countries	US
authorships[9].affiliations[0].institution_ids	https://openalex.org/I168537998
authorships[9].affiliations[0].raw_affiliation_string	Eli Lilly and Company, Indianapolis, IN, USA
authorships[9].institutions[0].id	https://openalex.org/I168537998
authorships[9].institutions[0].ror	https://ror.org/01qat3289
authorships[9].institutions[0].type	company
authorships[9].institutions[0].lineage	https://openalex.org/I168537998
authorships[9].institutions[0].country_code	US
authorships[9].institutions[0].display_name	Eli Lilly (United States)
authorships[9].author_position	middle
authorships[9].raw_author_name	K. Liming
authorships[9].is_corresponding	False
authorships[9].raw_affiliation_strings	Eli Lilly and Company, Indianapolis, IN, USA
authorships[10].author.id	https://openalex.org/A5027922287
authorships[10].author.orcid
authorships[10].author.display_name	Bente Frimodt‐Moller
authorships[10].affiliations[0].raw_affiliation_string	Eli Lilly Denmark A/S, Herlev, Denmark
authorships[10].author_position	middle
authorships[10].raw_author_name	B. Frimodt-Moller
authorships[10].is_corresponding	False
authorships[10].raw_affiliation_strings	Eli Lilly Denmark A/S, Herlev, Denmark
authorships[11].author.id	https://openalex.org/A5054055121
authorships[11].author.orcid	https://orcid.org/0009-0001-3819-9743
authorships[11].author.display_name	K. Park
authorships[11].countries	US
authorships[11].affiliations[0].institution_ids	https://openalex.org/I1343551460
authorships[11].affiliations[0].raw_affiliation_string	Department of Thoracic/Head & Neck Medical Oncology, UT, MD Anderson Cancer Center, Houston, TX, USA
authorships[11].institutions[0].id	https://openalex.org/I1343551460
authorships[11].institutions[0].ror	https://ror.org/04twxam07
authorships[11].institutions[0].type	healthcare
authorships[11].institutions[0].lineage	https://openalex.org/I1343551460
authorships[11].institutions[0].country_code	US
authorships[11].institutions[0].display_name	The University of Texas MD Anderson Cancer Center
authorships[11].author_position	last
authorships[11].raw_author_name	K. Park
authorships[11].is_corresponding	False
authorships[11].raw_affiliation_strings	Department of Thoracic/Head & Neck Medical Oncology, UT, MD Anderson Cancer Center, Houston, TX, USA
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	http://www.esmoopen.com/article/S205970292400382X/pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10417
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9987000226974487
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2740
primary_topic.subfield.display_name	Pulmonary and Respiratory Medicine
primary_topic.display_name	Lung Cancer Treatments and Mutations
related_works	https://openalex.org/W2064573700, https://openalex.org/W2967366602, https://openalex.org/W2376385980, https://openalex.org/W1496498748, https://openalex.org/W2129774558, https://openalex.org/W1997032381, https://openalex.org/W1979593122, https://openalex.org/W2287922696, https://openalex.org/W2190548886, https://openalex.org/W2783341158
cited_by_count	8
counts_by_year[0].year	2025
counts_by_year[0].cited_by_count	5
counts_by_year[1].year	2024
counts_by_year[1].cited_by_count	3
locations_count	1
best_oa_location.id	doi:10.1016/j.esmoop.2024.102614
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4210217024
best_oa_location.source.issn	2059-7029
best_oa_location.source.type	journal
best_oa_location.source.is_oa	True
best_oa_location.source.issn_l	2059-7029
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	True
best_oa_location.source.display_name	ESMO Open
best_oa_location.source.host_organization	https://openalex.org/P4310320990
best_oa_location.source.host_organization_name	Elsevier BV
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320990
best_oa_location.license	cc-by-nc-nd
best_oa_location.pdf_url	http://www.esmoopen.com/article/S205970292400382X/pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc-nd
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	ESMO Open
best_oa_location.landing_page_url	https://doi.org/10.1016/j.esmoop.2024.102614
primary_location.id	doi:10.1016/j.esmoop.2024.102614
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4210217024
primary_location.source.issn	2059-7029
primary_location.source.type	journal
primary_location.source.is_oa	True
primary_location.source.issn_l	2059-7029
primary_location.source.is_core	True
primary_location.source.is_in_doaj	True
primary_location.source.display_name	ESMO Open
primary_location.source.host_organization	https://openalex.org/P4310320990
primary_location.source.host_organization_name	Elsevier BV
primary_location.source.host_organization_lineage	https://openalex.org/P4310320990
primary_location.license	cc-by-nc-nd
primary_location.pdf_url	http://www.esmoopen.com/article/S205970292400382X/pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc-nd
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	ESMO Open
primary_location.landing_page_url	https://doi.org/10.1016/j.esmoop.2024.102614
publication_date	2024-03-01
publication_year	2024
referenced_works_count	0
abstract_inverted_index.%	270
abstract_inverted_index.a	2, 64, 114, 143, 173, 334, 351
abstract_inverted_index.26	160
abstract_inverted_index.36	190
abstract_inverted_index.4%	250
abstract_inverted_index.69	105
abstract_inverted_index.At	188
abstract_inverted_index.In	104, 129, 241, 337
abstract_inverted_index.an	85
abstract_inverted_index.as	257
abstract_inverted_index.at	63, 166, 384
abstract_inverted_index.by	44, 80, 84, 259
abstract_inverted_index.in	223, 237, 333, 355
abstract_inverted_index.is	1, 36
abstract_inverted_index.mg	69
abstract_inverted_index.mo	118, 127, 147, 177, 191, 280, 290, 297, 307, 314, 324
abstract_inverted_index.of	15, 23, 67, 93, 116, 125, 145, 154, 175, 185, 195, 201, 239, 377
abstract_inverted_index.on	20
abstract_inverted_index.or	47, 54
abstract_inverted_index.to	247, 252, 255, 277, 343, 380
abstract_inverted_index.up	180
abstract_inverted_index.1.1	82
abstract_inverted_index.11%	243
abstract_inverted_index.160	68
abstract_inverted_index.247	130
abstract_inverted_index.53%	238
abstract_inverted_index.57%	194
abstract_inverted_index.62%	141
abstract_inverted_index.66%	200
abstract_inverted_index.83%	112
abstract_inverted_index.85%	171
abstract_inverted_index.9.4	176
abstract_inverted_index.AEs	253
abstract_inverted_index.CNS	164
abstract_inverted_index.III	371
abstract_inverted_index.ORR	110, 139
abstract_inverted_index.OS,	325
abstract_inverted_index.PCR	46
abstract_inverted_index.RET	8, 16, 41, 358, 382
abstract_inverted_index.The	30, 71, 207, 216
abstract_inverted_index.and	5, 102, 123, 152, 183, 199, 228, 347, 363
abstract_inverted_index.any	234
abstract_inverted_index.due	246, 251
abstract_inverted_index.end	73
abstract_inverted_index.for	12, 34
abstract_inverted_index.had	56, 133, 162
abstract_inverted_index.mo)	122, 151, 182
abstract_inverted_index.mo.	156, 187
abstract_inverted_index.new	335
abstract_inverted_index.tab	336
abstract_inverted_index.the	13, 21, 24, 109, 138, 168, 189, 260, 338, 364, 369, 375
abstract_inverted_index.was	75, 111, 140, 170, 211
abstract_inverted_index.who	50, 55, 132
abstract_inverted_index.(55,	273
abstract_inverted_index.(72,	275
abstract_inverted_index.(95%	271, 281, 298, 315
abstract_inverted_index.(OS)	101
abstract_inverted_index.11.0	186
abstract_inverted_index.20.3	117
abstract_inverted_index.22.0	126
abstract_inverted_index.25.8	181
abstract_inverted_index.26.2	155
abstract_inverted_index.31.6	146
abstract_inverted_index.37.1	121
abstract_inverted_index.39.5	150
abstract_inverted_index.AEs,	248
abstract_inverted_index.BID.	70
abstract_inverted_index.DoR,	291
abstract_inverted_index.Dose	231
abstract_inverted_index.I/II	26
abstract_inverted_index.NGS,	45
abstract_inverted_index.Open	331
abstract_inverted_index.PFS,	308
abstract_inverted_index.both	158
abstract_inverted_index.data	33, 362
abstract_inverted_index.dose	66
abstract_inverted_index.from	233, 368
abstract_inverted_index.mDoR	115, 144
abstract_inverted_index.mPFS	124, 153
abstract_inverted_index.most	217
abstract_inverted_index.rate	78
abstract_inverted_index.show	344
abstract_inverted_index.were	51, 61, 205, 226
abstract_inverted_index.with	39, 113, 142, 172, 213, 264, 350, 357
abstract_inverted_index.%41.1	309
abstract_inverted_index.%44.7	292
abstract_inverted_index.%56.6	326
abstract_inverted_index.(AEs)	221
abstract_inverted_index.(ORR)	79
abstract_inverted_index.68)83	274
abstract_inverted_index.75.9)	330
abstract_inverted_index.CI)62	272
abstract_inverted_index.FISH)	48
abstract_inverted_index.NE)NE	318
abstract_inverted_index.NSCLC	18, 35, 49
abstract_inverted_index.These	361
abstract_inverted_index.based	19
abstract_inverted_index.cause	235
abstract_inverted_index.final	31, 339
abstract_inverted_index.phase	25, 370
abstract_inverted_index.point	74
abstract_inverted_index.table	332
abstract_inverted_index.total	242
abstract_inverted_index.trial	27, 372
abstract_inverted_index.≥G3	222
abstract_inverted_index.(15.4,	285
abstract_inverted_index.(16.5,	302
abstract_inverted_index.(19.3,	300
abstract_inverted_index.(20.4,	283
abstract_inverted_index.(22.0,	295
abstract_inverted_index.(22.3,	312
abstract_inverted_index.(34.2,	310
abstract_inverted_index.(35.7,	293
abstract_inverted_index.(35.9,	317
abstract_inverted_index.(37.8,	319
abstract_inverted_index.(49.8,	327
abstract_inverted_index.(52.4,	329
abstract_inverted_index.(DoR),	95
abstract_inverted_index.(PFS),	98
abstract_inverted_index.Across	157
abstract_inverted_index.NSCLC.	360
abstract_inverted_index.RECIST	81
abstract_inverted_index.alive.	206
abstract_inverted_index.common	218
abstract_inverted_index.events	220
abstract_inverted_index.follow	179
abstract_inverted_index.highly	3
abstract_inverted_index.kinase	9
abstract_inverted_index.naïve	53, 107, 203, 268
abstract_inverted_index.potent	6
abstract_inverted_index.recent	365
abstract_inverted_index.review	87
abstract_inverted_index.safety	209, 353
abstract_inverted_index.≥10%	224
abstract_inverted_index.(median	119, 148, 178
abstract_inverted_index.CI)26.2	299
abstract_inverted_index.CI)31.6	282
abstract_inverted_index.CI)47.6	316
abstract_inverted_index.CNS-ORR	169
abstract_inverted_index.adverse	219
abstract_inverted_index.durable	345
abstract_inverted_index.fusions	383
abstract_inverted_index.genomic	378
abstract_inverted_index.groups,	159
abstract_inverted_index.initial	385
abstract_inverted_index.overall	99, 208
abstract_inverted_index.primary	72
abstract_inverted_index.profile	210, 354
abstract_inverted_index.related	254
abstract_inverted_index.results	22, 367
abstract_inverted_index.safety.	103
abstract_inverted_index.testing	379
abstract_inverted_index.treated	197, 263
abstract_inverted_index.(Table).	128
abstract_inverted_index.91)mTime	276
abstract_inverted_index.AST/ALT.	230
abstract_inverted_index.CNS-mDoR	174
abstract_inverted_index.CNS-mPFS	184
abstract_inverted_index.N=69ORR,	269
abstract_inverted_index.Patients	38
abstract_inverted_index.activity	349
abstract_inverted_index.approved	11
abstract_inverted_index.assessed	83, 258
abstract_inverted_index.duration	92
abstract_inverted_index.enrolled	62
abstract_inverted_index.identify	381
abstract_inverted_index.included	91
abstract_inverted_index.landmark	192
abstract_inverted_index.occurred	236
abstract_inverted_index.patients	131, 161, 198, 204, 225, 356
abstract_inverted_index.positive	366
abstract_inverted_index.previous	214
abstract_inverted_index.received	58, 135
abstract_inverted_index.reports.	215
abstract_inverted_index.response	77, 94
abstract_inverted_index.survival	97, 100
abstract_inverted_index.35.7)22.0	301
abstract_inverted_index.42.3)20.3	284
abstract_inverted_index.47.3)mOS,	313
abstract_inverted_index.47.9)34.6	311
abstract_inverted_index.53.4)35.4	294
abstract_inverted_index.62.8)65.6	328
abstract_inverted_index.Response,	278
abstract_inverted_index.Secondary	89
abstract_inverted_index.advanced,	40
abstract_inverted_index.analysis,	340
abstract_inverted_index.baseline,	167
abstract_inverted_index.continued	342
abstract_inverted_index.endpoints	90
abstract_inverted_index.estimate,	193
abstract_inverted_index.follow-up	120, 149
abstract_inverted_index.including	249
abstract_inverted_index.increased	229
abstract_inverted_index.inhibitor	10
abstract_inverted_index.objective	76
abstract_inverted_index.patients,	108
abstract_inverted_index.patients.	240
abstract_inverted_index.reduction	232
abstract_inverted_index.reinforce	374
abstract_inverted_index.reported.	37
abstract_inverted_index.responses	346
abstract_inverted_index.selective	4
abstract_inverted_index.treatment	14, 52, 106, 202, 245
abstract_inverted_index.49.0)mPFS,	296
abstract_inverted_index.CNS-active	7
abstract_inverted_index.committee.	88
abstract_inverted_index.consistent	212
abstract_inverted_index.diagnosis.	386
abstract_inverted_index.follow-up,	288, 305, 322
abstract_inverted_index.importance	376
abstract_inverted_index.manageable	352
abstract_inverted_index.measurable	163
abstract_inverted_index.metastases	165
abstract_inverted_index.previously	57, 134, 196
abstract_inverted_index.(identified	43
abstract_inverted_index.independent	86
abstract_inverted_index.LIBRETTO-001	28, 32
abstract_inverted_index.chemotherapy	60, 266
abstract_inverted_index.discontinued	244
abstract_inverted_index.hypertension	227
abstract_inverted_index.intracranial	348
abstract_inverted_index.mo39.537.136	289
abstract_inverted_index.mo41.238.936	306
abstract_inverted_index.mo44.641.936	323
abstract_inverted_index.35PPreviously	262
abstract_inverted_index.LIBRETTO-431,	373
abstract_inverted_index.NE)Censoring,	320
abstract_inverted_index.Selpercatinib	0
abstract_inverted_index.chemotherapy,	137
abstract_inverted_index.mo1.91.8mDoR,	279
abstract_inverted_index.selpercatinib	65, 256, 341
abstract_inverted_index.(NCT03157128).	29
abstract_inverted_index.N=247Treatment	267
abstract_inverted_index.platinum-based	59, 136, 265
abstract_inverted_index.%46.244.9Median	304
abstract_inverted_index.%49.343.9Median	287
abstract_inverted_index.%55.562.3Median	321
abstract_inverted_index.24.9)Censoring,	303
abstract_inverted_index.29.5)Censoring,	286
abstract_inverted_index.fusion-positive	17, 42, 359
abstract_inverted_index.progression-free	96
abstract_inverted_index.investigator.Table:	261
cited_by_percentile_year.max	99
cited_by_percentile_year.min	96
countries_distinct_count	7
institutions_distinct_count	12
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.8299999833106995
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.95112094
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	True